Indian drugmaker Cipla beats profit view on steady respiratory drugs demand ReutersOctober 30, 2025 at 3:38 AM 0 Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015.
- - Indian drugmaker Cipla beats profit view on steady respiratory drugs demand
ReutersOctober 30, 2025 at 3:38 AM
0
Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015. REUTERS/Danish Siddiqui
(Reuters) -India's Cipla reported a better-than-expected second-quarter profit on Thursday, driven by steady demand for its respiratory drugs.
The country's third-largest drugmaker by sales posted a 3.7% rise in consolidated net profit to 13.51 billion rupees ($153.7 million) in the quarter ended September 30, beating analysts' estimates of 13.47 billion rupees billion rupees, per data compiled by LSEG.
Total revenue increased 7.6% to 75.89 billion rupees, slightly above expectations of 74.30 billion rupees.
The company has been facing pricing pressure on its generic version of Bristol Myers Squibb's cancer drug Revlimid, a key revenue driver in the U.S. market.
The drug is set to go off patent next year, opening the door to more competitors and intensifying price competition.
Last week, rival Dr Reddy's reported a quarterly profit that missed analysts' estimates and a 13% drop in its North America sales.
($1 = 87.8950 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by Mrigank Dhaniwala and Nivedita Bhattacharjee)
Source: "AOL Money"
Source: EVENING MAG
Full Article on Source: EVENING MAG
#LALifestyle #USCelebrities
